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Abstract
Most previous genetic epidemiology studies within the field of osteoporosis have focused on the genetics of the complex
trait areal bone mineral density (aBMD), not being able to differentiate genetic determinants of cortical volumetric BMD
(vBMD), trabecular vBMD, and bone microstructural traits. The objective of this study was to separately identify genetic
determinants of these bone traits as analysed by peripheral quantitative computed tomography (pQCT). Separate GWA
meta-analyses for cortical and trabecular vBMDs were performed. The cortical vBMD GWA meta-analysis (n = 5,878) followed
by replication (n = 1,052) identified genetic variants in four separate loci reaching genome-wide significance (RANKL,
rs1021188, p = 3.6610214; LOC285735, rs271170, p = 2.7610212; OPG, rs7839059, p = 1.2610210; and ESR1/C6orf97,
rs6909279, p = 1.161029). The trabecular vBMD GWA meta-analysis (n = 2,500) followed by replication (n = 1,022) identified
one locus reaching genome-wide significance (FMN2/GREM2, rs9287237, p = 1.961029). High-resolution pQCT analyses,
giving information about bone microstructure, were available in a subset of the GOOD cohort (n = 729). rs1021188 was
significantly associated with cortical porosity while rs9287237 was significantly associated with trabecular bone fraction. The
genetic variant in the FMN2/GREM2 locus was associated with fracture risk in the MrOS Sweden cohort (HR per extra T allele
0.75, 95% confidence interval 0.60–0.93) and GREM2 expression in human osteoblasts. In conclusion, five genetic loci
associated with trabecular or cortical vBMD were identified. Two of these (FMN2/GREM2 and LOC285735) are novel bone-
related loci, while the other three have previously been reported to be associated with aBMD. The genetic variants
associated with cortical and trabecular bone parameters differed, underscoring the complexity of the genetics of bone
parameters. We propose that a genetic variant in the RANKL locus influences cortical vBMD, at least partly, via effects on
cortical porosity, and that a genetic variant in the FMN2/GREM2 locus influences GREM2 expression in osteoblasts and
thereby trabecular number and thickness as well as fracture risk.
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Introduction
Meta-analyses of genome-wide association studies (GWAS) have
identified a large number of loci associated with areal bone
mineral density (aBMD) [1–6]. aBMD is a complex trait, obtained
from a 2-dimensional projectional scan of the given bone with dual
x-ray absorptiometry (DXA). Skeletal sites which are measured in
this way, such as the lumbar spine and hip, comprise a mixture of
cortical bone (compact bone comprising the outer shell), and
trabecular bone (a network of thin interconnecting plates within
the marrow cavity of vertebrae and the end of long bones). The
lumbar spine has a relatively high proportion of trabecular bone,
whereas the hip has a higher proportion of cortical bone. DXA-
measured aBMD depends not only on bone cross-sectional size but
also on apparent volumetric bone mineral density which is largely
determined by trabecular microstructure and cortical thickness
[7]. Although aBMD is the gold standard for diagnosing
osteoporosis, it fails to provide a detailed skeletal phenotype
necessary to discern traits such as trabecular volumetric BMD
(vBMD), cortical vBMD and bone microstructural parameters.
Previous studies using DXA have demonstrated that age is a major
predictor of fracture risk independent of aBMD. Although this
aBMD independent effect of age has been attributed to poor bone
‘‘quality’’, the structural basis for this remains unclear [8]. Age-
related changes in bone include microstructural deterioration,
such as trabecular perforation, thinning, and loss of connectivity,
as well as increased cortical porosity [8,9]. Quantitative computed
tomography (QCT) analysis has the capacity to reveal unique
information about these bone traits.
Standard peripheral QCT (pQCT) with a resolution of 500 mm
has the advantage of being able to separately analyse trabecular
and cortical vBMDs. The correlation between trabecular and
cortical vBMDs is low (rs 0.11 in the young adult men of the
GOOD cohort; [10]), supporting the notion that the determinants
of these two bone parameters differ. Cortical vBMD but not
trabecular vBMD reflects material density while trabecular vBMD
mainly is influenced by trabecular number and thickness. In
addition, the correlations of these vBMD parameters with femoral
neck aBMD are low (cortical vBMD, rs 0.04) or moderate
(trabecular vBMD rs 0.65), suggesting that cortical and trabecular
vBMDs are at least partly influenced by genetic determinants not
possible to identify by a GWAS of aBMD [10]. The heritability for
trabecular vBMD has been reported to be as high as 59% while
the heritability for cortical vBMD was slightly lower (40%) [11].
GWAS have revealed differences in genetic associations with
lumbar and hip aBMD, providing some evidence that cortical and
trabecular bone have distinct genetic influences [2].
We have in a previous smaller-scale GWAS meta-analysis
(n = 1,934) identified a genetic variant in the RANKL locus to be
significantly associated with cortical vBMD [10]. The genetic
determinants of trabecular vBMD have not yet been evaluated
using GWAS.
High resolution pQCT (HRpQCT) not only allows the
separation of the trabecular and cortical bone compartments but
also the assessment of bone microstructure. HRpQCT has an
isotrophic voxel size of 82 mm and shows excellent correlation with
ex vivo mCT imaging (resolution 20 mm or better) [8,12,13].
Importantly, HRpQCT analysis recently demonstrated that
younger and older subjects with the same aBMD differed in
cortical porosity, a key parameter not captured by DXA [8]. The
genetic determinants of trabecular and cortical bone microstruc-
ture parameters as analysed by HRpQCT are unknown.
The objective of the present study was to identify genetic
determinants of vBMDs and bone microstructure parameters
separately for the cortical and trabecular bone compartments as
analyzed by pQCT and HRpQCT. As our assembled discovery
cohort was larger for the pQCT measurements (cortical vBMD
n=5,878, trabecular vBMD n=2,500) than for the HRpQCT
measurements (n = 729), we aimed to first identify genome-wide
significant genetic variants for cortical and trabecular vBMDs
separately and then to evaluate the impact of the identified
variants on trabecular and cortical bone microstructure parame-
ters in the HRpQCT cohort.
Results
Genome-wide association (GWA) meta-analyses of
cortical and trabecular vBMDs
Table 1 displays the anthropometrics and bone traits for the
four cohorts (ALSPAC discovery, GOOD baseline discovery, YFS
discovery, and MrOS Sweden replication) evaluated. The
association between cortical vBMD and trabecular vBMD was
rather modest (Spearman’s rank correlation coefficient [rho]
GOOD baseline r = 0.11 [10]; GOOD five year follow-up r =20.01).
Separate GWA meta-analyses for cortical and trabecular vBMD
were performed including all three discovery cohorts for cortical
vBMD while trabecular vBMD was available in the YFS and
GOOD cohorts.
GWA meta-analysis of cortical vBMD
Inverse variance weighted fixed-effect model meta-analysis of
study-specific results was performed. In the cortical vBMD GWA
meta-analysis of the ALSPAC, GOOD and YFS cohorts there was
little systematic inflation of test statistics (Overall l=1.012 (1.023
for ALSPAC; 1.013 for GOOD; 1.023 for YFS)), but a marked
deviation from the null distribution amongst the lowest observed
p-values (Figure 1A). We identified genetic variants in four
separate loci reaching genome-wide significance (Figure 1B). The
greatest evidence for association between genetic variation and
cortical vBMD was seen for rs1021188 (0.15 SD decrease per C
Author Summary
Osteoporosis is a common highly heritable skeletal disease
characterized by reduced bone mineral density (BMD) and
deteriorated bone microstructure, resulting in an increased
risk of fracture. Most previous genetic epidemiology
studies have focused on the genetics of the complex trait
BMD, not being able to separate genetic determinants of
the trabecular and cortical bone compartments and bone
microstructure. The trabecular and cortical BMDs can be
analysed separately by computed tomography. Therefore,
we performed separate genome-wide association studies
for trabecular and cortical BMDs, demonstrating that the
genetic determinants of cortical and trabecular BMDs
differ. Genetic variants in the RANKL, LOC285735, OPG, and
ESR1 loci were associated with cortical BMD, while a
genetic variant in the FMN2/GREM2 locus was associated
with trabecular BMD. Two of these are novel bone-related
loci. Follow-up analyses of bone microstructure demon-
strated that a genetic variant in the RANKL locus is
associated with cortical porosity and that the FMN2/GREM2
locus is associated with trabecular number and thickness.
We propose that a genetic variant in the RANKL locus
influences cortical BMD via effects on cortical porosity, and
that a genetic variant in the FMN2/GREM2 locus influences
trabecular BMD and fracture risk via effects on both
trabecular number and thickness.
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allele; p = 1.4610212) on chromosome 13, slightly upstream of the
RANKL gene (TNFSF11; Table 2, Figure 2A, Table S1). The
second strongest genetic signal for cortical vBMD (rs271170; 0.11
SD decrease per T allele, p = 2.9610211) is a novel bone-related
locus, located on chromosome 6, upstream of LOC285735 (Table 2,
Figure 2B, Table S1). The third strongest signal (rs7839059, 0.10
SD decrease per A allele, p = 4.161029) was located on
chromosome 8, upstream of OPG (TNFRSF11B; Table 2,
Figure 2C, Table S1). The fourth genome-wide signal
(rs6909279, 0.09 SD decrease per allele G, p= 1.061028) was
located on chromosome 6, in C6orf97 upstream and close to estrogen
receptor-a (ESR1; Table 2, Figure 2D, Table S1).
We selected our top four regions and carried out analyses
conditional on the most associated SNPs in each region. When
conditioning on the most significant SNP in the RANKL region
(rs1021188) an additional suggestive signal (rs17638544 close to
AKAP1 and upstream of RANKL, p = 4.261025) appeared, but did
not achieve genome-wide significance (Table 2, Figure 2E, Table
S1). Using similar conditional analysis, no additional SNPs with an
independent signal appeared in the other three evaluated regions
(p,561025).
The RANKL, OPG and ESR1 regions have earlier been reported
to be associated with aBMD in large scale GWA meta-analyses [1–
6]. To evaluate if the identified SNPs associated with cortical
vBMD in these regions are independent from the previously
reported aBMD related SNPs, conditional analyses were per-
formed (RANKL region, rs1021188 and rs17638544 were condi-
tioned on the known aBMD hit rs9533090; OPG region, rs7839059
Table 1. Characteristics of the cohorts included in the discovery GWA meta-analyses and replications.
Discovery Replication
ALSPAC GOOD YFS MrOS Sweden
(n =3382) (n=938) (n=1558) (n =1052)
mean sd mean sd mean sd mean sd
Age, years 15.5 0.3 18.9 0.6 38 5.0 78.7 3.0
Men, % 47 100 44.5 100
Height, cm 169.3 8.3 181.7 6.6 172.1 9.0 173.9 6.4
Weight, kg 61.2 11.3 73.9 11.6 77 16.4 79.2 11.2
Cortical
Position of section 50% 25% 30% 38%
vBMD, mg/cm3 1101 38 1156 20 1159 24 1128 40.8
Trabecular
Position of section NA NA 4% 5% 4%
vBMD, mg/cm3 NA NA 266 34 241 34 217 37
Position = Position of section in proximal direction from distal end of tibia.
vBMD= volumetric bone mineral density; NA=not available.
doi:10.1371/journal.pgen.1003247.t001
Figure 1. Genome-wide meta-analysis of cortical vBMD. (A) QQ plots of the genome-wide meta-analysis of cortical vBMD without (filled
circles) or with (open diamonds) removal of the genome-wide significant loci (All SNPs excluded 61 Mb around the hits). (B) Manhattan plot of the
genome-wide meta-analysis of cortical vBMD.
doi:10.1371/journal.pgen.1003247.g001
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was conditioned on the known aBMD hit rs2062377; ESR1 region,
rs6909279 was conditioned on known aBMD hits rs7751941 and
rs4869742; [2]). The two cortical vBMD RANKL signals
(rs1021188 and rs17638544) were distinct from the previously
reported aBMD signal (rs9533090; [2]) in this region, supported
by the fact that (i) rs9533090 was not significantly associated with
cortical vBMD (Figure 2A), (ii) adjustment for rs9533090 did not
influence the associations for rs1021188 or rs17638544 with
cortical vBMD and the two cortical vBMD signals displayed a low
r2 (,0.04) with rs9533090 (Table S2). It is difficult to determine if
the identified cortical vBMD signal in the OPG region is separate
from the previous reported aBMD signal in this region (rs2062377;
[2]) as this previous aBMD signal also was significantly associated
with cortical vBMD (Figure 2C), the r2 between the two SNPs was
0.39, and adjustment for rs2062377 slightly but not completely
attenuated the association for rs7839059 with cortical vBMD
(Table S2).
The identified cortical vBMD SNP in the ESR1 region
(rs6909279) is independent from one of the previous reported
aBMD signals (rs7751941) while the other reported independent
aBMD SNP in this region (rs4869742 [2]) displayed a relatively
high r2 with rs6909279 (r2 = 0.60) (Figure 2D). However,
adjustment for rs4869742 only slightly attenuated the association
for rs6909279 with cortical vBMD (Table S2).
GWA meta-analysis of trabecular volumetric BMD. In
the trabecular vBMD GWA meta-analysis there was little
systematic inflation of test statistics (Overall l=1.005 (1.020 for
GOOD; 1.018 for YFS)), but a significant deviation from the null
distribution amongst the lowest observed p-values (Figure 3A). We
identified one novel bone-related genetic variant reaching
genome-wide significance (Figure 3B). The greatest evidence for
association between genetic variation and trabecular vBMD was
seen for rs9287237 (0.22 SD increase per T allele; p = 3.361028)
on chromosome 1, in the formin 2 gene (FMN2 gene; Table 2,
Figure 2. Regional association plots for the 5 independent signals from the discovery genome-wide meta-analysis of cortical vBMD.
(A) rs1021188, (B) rs271170, (C) rs7839059, (D) rs6909279, (E) rs17638544. Circles show the GWA meta-analysis p-values, with different colors
indicating varying linkage disequilibrium with the indicated SNP (diamond). SNPs in the same region identified in a recent large-scale GWA meta-
analysis of aBMD are indicated by a red outer circle [2]. LocusZoom: http://csg.sph.umich.edu/locuszoom/.
doi:10.1371/journal.pgen.1003247.g002
Genetic Determinants of Bone Microstructure
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Figure 4, Table S1). When conditioning on the most significant
SNP in the FMN2 region, no additional SNPs with an independent
signal appeared (p,561025).
The rs9287237 SNP significantly associated with trabecular
vBMD was not associated with cortical vBMD, and three of the
four genome-wide significant cortical vBMD SNPs were not
significantly associated with trabecular vBMD (Table 3). However,
the cortical vBMD SNP rs7839059 upstream of OPG displayed a
modest association with trabecular vBMD (0.06 SD decrease per
A allele; p = 4.761022) in the same direction as seen for the
genome-wide significant association with cortical vBMD (Table 3).
Replication study of top SNPs for cortical and trabecular
vBMD
Cortical vBMD. Five SNPs (four genome-wide significant
[rs1021188, rs271170, rs7839059 and rs6909279] and one
identified in the conditional analyses rs17638544) were selected
for replication in the MrOS Sweden cohort. In this replication
analysis all five SNPs were significantly associated with cortical
vBMD in the same direction and with similar effect sizes as found
in the discovery GWA meta-analysis (Table 2; Combined all
cohorts, rs1021188 0.15 SD decrease per C allele, p = 3.6610214;
rs271170 0.11 SD decrease per T allele, p = 2.7610212; rs7839059
0.10 SD decrease per A allele, p = 1.2610210; rs6909279 0.09 SD
decrease per G allele, p = 1.161029; rs17638544 0.13 SD increase
per T allele, p = 5.161026). The four GWA significant cortical
vBMD SNPs rs1021188, rs271170, rs7839059 and rs6909279
explained 0.6%, 0.4%, 0.6% and 0.3%, respectively of the
variation in cortical vBMD in the elderly men of the MrOS
Sweden replication cohort. When including all four SNPs
together, 1.5% of the variation in cortical vBMD was explained
in the MrOS Sweden replication cohort. There was evidence for
Table 2. Top cortical and trabecular vBMD signals from pQCT GWA meta-analyses followed by replication.
Discovery Replication Combined
Meta-analysis MrOS All cohorts
SNP Closest gene Chr
Effect
allele EAF n Beta SE P n EAF Beta SE p n Effect SE p
Cortical vBMD
rs1021188 TNFSF11 13 C 0.17 5878 20.15 0.02 1.4E-12 1052 0.15 20.15 0.06 7.0E-03 6930 20.15 0.02 3.6E-14
rs271170 LOC285735 6 T 0.33 5878 20.11 0.02 2.9E-11 1025 0.29 20.10 0.05 3.0E-02 6903 20.11 0.02 2.7E-12
rs7839059 TNFRSF11B 8 A 0.34 5878 20.10 0.02 4.1E-09 1025 0.33 20.11 0.04 9.0E-03 6903 20.10 0.02 1.2E-10
rs6909279 C6orf97/ESR1 6 G 0.40 5878 20.09 0.02 1.0E-08 1027 0.38 20.09 0.04 3.8E-02 6905 20.09 0.01 1.1E-09
rs17638544* TNFSF11 13 T 0.07 5873 0.13 0.03 4.2E-05 1009 0.06 0.18 0.09 3.8E-02 6882 0.13 0.03 5.1E-06
Trabecular vBMD
rs9287237 FMN2 1 T 0.15 2500 0.22 0.04 3.3E-08 1022 0.18 0.14 0.06 9.0E-03 3522 0.19 0.03 1.9E-09
Models adjusted for sex (ALSPAC and YFS), age, height, weight (ln). Betas in standard deviations and standard errors are presented.
*conditional adjusted for rs1021188; vBMD= volumetric bone mineral density; EAF = effect allele frequency.
doi:10.1371/journal.pgen.1003247.t002
Figure 3. Genome-wide meta-analysis of trabecular vBMD. (A) QQ plot of the genome-wide meta-analysis of trabecular vBMD. (B) Manhattan
plot of the genome-wide meta-analysis of trabecular vBMD.
doi:10.1371/journal.pgen.1003247.g003
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heterogeneity in the meta-analyses of the associations with
rs1021188 (het p = 0.028) and rs17638544 (het p = 0.011).
Random effects meta-analysis results for rs1021188 and
rs17638544 were 0.18 SD per allele (SE= 0.05, 95% CI 0.08 to
0.28, p= 0.0003) and 0.14 SD per allele (SE= 0.07, 95% CI 0.00
to 0.28, p = 0.056), respectively.
Trabecular vBMD. One SNP (rs9287237) was replicated in
the MrOS Sweden cohort and it was significantly associated with
trabecular vBMD also in the replication cohort (Table 2; Combined
all cohorts, 0.19 SD increase per T allele, p = 1.961029). rs9287237
explained 0.7% of the variation in trabecular vBMD in the MrOS
Sweden replication cohort.
Figure 4. Regional association plot for rs9287237 of the discovery genome-wide meta-analysis of trabecular vBMD. Circles show the
GWA meta-analysis p-values, with different colors indicating varying linkage disequilibrium with rs9287237 (diamond). LocusZoom: http://csg.sph.
umich.edu/locuszoom/.
doi:10.1371/journal.pgen.1003247.g004
Table 3. Association of cortical and trabecular vBMD with top cortical and trabecular vBMD SNPs.
Present pQCT meta-analysis GEFOS aBMD meta-analysis
Cortical vBMD Trabecular vBMD FN BMD LS BMD
SNP
Closest
gene Chr
Effect
allele EAF n Beta SE P n Beta SE P nGEFOS EAF Dir PGEFOS nGEFOS EAF Dir PGEFOS
Cortical vBMD SNPs
rs1021188 TNFSF11 13 C 0.17 5952 20.15 0.02 1.4E-12 2500 20.01 0.04 8.5E-01 32961 0.14 2 1.7E-02 31800 0.14 2 2.2E-02
rs271170 LOC285735 6 T 0.33 5952 20.11 0.02 2.9E-11 2500 0.02 0.03 5.4E-01 32961 0.29 + 5.4E-03 31800 0.29 + 6.9E-03
rs7839059 TNFRSF11B 8 A 0.34 5952 20.10 0.02 4.1E-09 2500 20.06 0.03 4.7E-02 32961 0.33 2 3.4E-17 31800 0.33 2 8.1E-16
rs6909279 C6orf97/ESR1 6 G 0.40 5952 20.09 0.02 1.0E-08 2500 20.04 0.03 2.0E-01 32961 0.46 2 2.5E-15 31800 0.46 2 5.3E-17
Trabecular vBMD SNPs
rs9287237 FMN2 1 T 0.15 5952 0.02 0.02 3.2E-01 2500 0.22 0.04 3.3E-08 32961 0.15 + 2.0E-04 31800 0.15 + 1.1E-03
Models adjusted for sex (ALSPAC and YFS), age, height, weight (ln). Betas in standard deviations and standard errors are presented. vBMD=volumetric bone mineral
density; EAF = effect allele frequency; nGEFOS and PGEFOS is the number of subjects and p values as given from the GEFOS consortium (http://www.gefos.org/
?q = content/data-release; [2]). Dir =Direction of the effect in the GEFOS publication using the same effect allele as in the present pQCT meta-analysis.
doi:10.1371/journal.pgen.1003247.t003
Genetic Determinants of Bone Microstructure
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Sex-specific analyses
Sex-specific analyses demonstrated that all five cortical vBMD
SNPs were significantly associated with cortical vBMD in both
men and women with effects in the same direction. However, the
magnitude of the effect sizes differed significantly according to sex
for three of the identified hits (Figure 5A; rs1021188 in RANKL
region, men 0.21 SD and women 0.06 SD decrease per C allele,
p = 4.361025; rs6909279 in ESR1 region, men 0.12 SD and women
0.05 SD decrease per G allele, p = 3.061023; rs7839059 in OPG
region, men 0.12 SD and women 0.07 SD decrease per A allele,
p = 3.061022). The sex difference may explain the heterogeneity
observed in the unstratified analyses for rs1021188 (both sexes
have a het p.0.05). Significant heterogeneity is still observed in
the males for rs17638544 (het p= 0.016).
The genetic variant associated with trabecular vBMD
(rs9287237) was significantly associated with trabecular vBMD
in men (Figure 5B, 0.22 SD increase per T allele) and a similar
non-significant tendency in the same direction was observed in
females (0.12 SD increase per T allele). It should be emphasized
that for trabecular vBMD, we had a low statistical power to detect
sex differences in effect sizes as the number of females included
was rather low (n= 865).
Genetic association versus HRpQCT measured bone
microstructure
At the five year follow-up of the GOOD cohort both pQCT
analysis, giving information about cortical and trabecular vBMD,
and HRpQCT analyses, giving information about trabecular bone
microstructure and cortical porosity, were available in the tibia for
729 subjects with genotype data available (Table 4). To determine
the impact of the identified genome-wide significant cortical and
trabecular vBMD signals for bone microstructure parameters,
their associations with HRpQCT parameters were evaluated in
the GOOD cohort. Trabecular vBMD as analysed by pQCT was
strongly (r = 0.94) associated with trabecular bone fraction (BV/
TV) as analysed by HRpQCT. The pQCT-derived cortical
vBMD was moderately inversely correlated to cortical porosity as
analysed by HRpQCT (r=20.21).
Cortical vBMD SNPs. The four genome-wide significant
cortical vBMD SNPs were all associated with (p,0.05) cortical but
not trabecular vBMD at the five year follow-up visit of the GOOD
cohort and their effect sizes for cortical vBMD were of similar
magnitude and direction as seen for the GOOD cohort at the
baseline visit (Tables S1 and S3, Figure 6). Interestingly,
rs1021188, being the SNP explaining most of the cortical vBMD
Figure 5. The genome-wide meta-analyses according to sex. (A) Cortical vBMD (rs1021188 effect allele =C, rs271170 effect allele = T, rs7839059
effect allele =A, rs6909279 effect allele =G, rs17638544 effect allele = T). (B) Trabecular vBMD for rs9287237 (effect allele = T). Mean and standard error
vBMD z-scores are shown for each cohort, stratified by sex. Diamonds show the combined z-scores estimates per genotype (the width of the
diamond represents the combined standard error). Disc = discovery cohort, repl = replication cohort.
doi:10.1371/journal.pgen.1003247.g005
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variation, was also associated with cortical porosity (0.15 SD
increase per C allele, p = 3.061022) but, as expected, in the
inverse direction compared with the association with cortical
vBMD (Figure 6 and Table S3).
Trabecular vBMD SNP. The genome-wide significant tra-
becular vBMD SNP rs9287237 was significantly associated with
trabecular but not cortical vBMD at the five year follow-up visit of
the GOOD cohort and the effect size (0.32 SD increase per T
allele, p = 2.661026) for trabecular vBMD was of similar
magnitude and direction as seen for the GOOD cohort at the
baseline visit (Tables S1 and S3, Figure 6). This SNP was also
significantly associated with trabecular bone fraction (BV/TV) as
analyzed by HRpQCT (0.29 SD increase per T allele,
p = 1.861025) while it was not significantly associated with
cortical porosity (Figure 6). Detailed analysis of trabecular bone
microstructure revealed that rs9287237 was not only associated
with trabecular bone fraction but also with trabecular number
(0.15 SD increase per T allele, p = 1.661022), trabecular thickness
(0.18 SD increase per T allele, p = 5.061023) and trabecular
spacing (0.20 SD decrease per T allele, p = 1.261023; Figure 6).
Estimation of the genetic correlation between cortical
and trabecular vBMD
Although there appeared to be no overlap in the identity of the
genome-wide significant SNPs between cortical and trabecular
vBMD, it is still possible that there are genetic variants lower down
the distribution of tests statistics which do not meet the stringent
criteria for genome-wide significance, but nevertheless affect both
traits pleiotropically. In order to investigate this possibility we ran
a bivariate REML analysis using the GCTA software package in
the GOOD cohort, having both cortical and trabecular vBMDs
measurements available [14]. GCTA estimated the genetic
correlation between trabecular and cortical BMD as rG=0.0
(SE= 0.39) suggesting an absence of common genetic variants
affecting both traits and consistent with our results from the
genome-wide association analysis. However, we note that there are
Table 4. Characteristics of the GOOD five year follow-up
cohort.
mean sd
Age, years 24.1 0.6
Men, no (%) 100
Height, cm 182.4 6.5
Weight, kg 78.6 12.1
pQCT (n = 729)
Trabecular vBMD (mg/cm3) 261.7 35.5
Cortical vBMD (mg/cm3) 1163.3 19.3
HRpQCT
Trabecular (729)
BV/TV (%) 18.3 2.7
TbN (mm21) 2.09 0.28
TbTh (mm) 88.1 11.1
TbSp (mm) 0.40 0.06
Cortical (n = 725)
Porosity (%) 3.04 1.16
vBMD= volumetric bone mineral density; BV/TV =bone volume per total
volume; TbN= trabecular number; TbTh = trabecular thickness;
TbSp= trabecular separation.
doi:10.1371/journal.pgen.1003247.t004
Figure 6. The associations of the SNPs explaining most of the cortical vBMD (rs1021188) and trabecular vBMD variations
(rs9287237), respectively, with bone parameters in the GOOD cohort at the follow-up visit (n=729). Mean and standard error z-scores
are shown for trabecular and cortical vBMDs as analyzed by pQCT, and for trabecular bone volume per total volume (BV/TV), trabecular number
(TbN), trabecular thickness (TbTh), trabecular separation (TbSp) and cortical porosity as analyzed by HRpQCT.
doi:10.1371/journal.pgen.1003247.g006
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relatively few individuals in this analysis and consequently the
standard errors on this estimate are very wide. In order to be more
definitive with respect to the possible existence of pleiotropy one
would need to perform the analysis in a much larger sample of
individuals to yield precise estimates of the genetic correlation
between the two traits.
Comparison of the impact of identified genome-wide
significant SNPs for vBMD and previously described
aBMD SNPs
All five genome-wide significant vBMD SNPs were nominally
significantly associated (p,0.05) with both femoral neck and
lumbar spine aBMD as provided in the public data release from
the discovery phase (n>32,000) of the recent aBMD analyses from
the GEFOS consortium (Table 3; http://www.gefos.org/
?q = content/data-release) [2]. The direction of the effect was
the same when comparing vBMDs and aBMD for four of the
SNPs while it was opposite to the one described for aBMD for the
cortical vBMD SNP rs271170.
When evaluating the 64 genome-wide significant aBMD SNPs
recently identified by the GEFOS consortium [2] it was found that
15 of these were also significantly associated (p,0.05) with cortical
vBMD and 15 were significantly associated with trabecular
vBMD. Four of these SNPs were associated with both cortical
and trabecular vBMDs (Table S4).
eQTL analysis in human osteoblasts
In an attempt to assess the underlying functional mechanism of
our identified loci we examined their potential role in regulating
gene expression using expression quantitative trait locus (eQTL)
data from resting (i.e. untreated) and induced (i.e. dexamethasone,
BMP-2 and PGE2 treated) primary human osteoblasts [15,16].
Expression of genes in close proximity to the five genome-wide
significant SNPs (defined as located within the gene 6250 kb) was
tested for association (Table S5). We found that the trabecular
vBMD-associated SNP (rs9287237) was the strongest SNP
significantly associated (P = 2.361024) with expression of the
nearby GREM2 gene. No significant effects on gene expression
were noted at the additional four loci (Bonferroni adjusted P.0.05
corresponding to 0.05/88=5.761024; Table S5).
Association with fractures in MrOS Sweden
Overall, 388 men had at least one validated incident fracture
after an average follow-up of 5.4 years in the MrOS Sweden
cohort (Table S6). The trabecular vBMD SNP rs9287237, but
none of the four cortical vBMD SNPs, was significantly associated
with risk of all fractures (HR per extra T allele 0.75, 95%
confidence interval (CI) 0.60–0.93) and hip fractures (HR per
extra T allele 0.59, 95% CI 0.36–0.98; Table S7).
In two centers of MrOS Sweden, Gothenburg and Malmo¨,
overall, 1445 men had a spine X-ray at baseline, which identified
225 men with prevalent vertebral fractures (15.6%; Table S6). The
trabecular vBMD SNP rs9287237, but none of the four cortical
vBMD SNPS, was significantly associated with prevalent X-ray
verified vertebral fractures (OR per extra T allele 0.68, 95% CI
0.50–0.94; Table S7).
Discussion
Osteoporosis is a common highly heritable skeletal disease
characterized by reduced aBMD and deteriorated bone micro-
structure, resulting in an increased risk of fragility fracture [17].
Most previous genetic epidemiology studies have focused on the
genetics of the complex trait aBMD, not being able to separate
genetic determinants of trabecular vBMD, cortical vBMD and
bone microstructure. However, all these structural traits are
determinants of aBMD [7]. We, herein, provide evidence that the
genetic determinants of cortical and trabecular vBMDs differ.
Separate GWAS meta-analyses of cortical and trabecular vBMDs
demonstrated that genetic variants in the RANKL, LOC285735,
OPG and ESR1 loci were associated with cortical vBMD while a
genetic variant in the FMN2/GREM2 locus was associated with
trabecular vBMD. Follow-up analyses in a HRpQCT cohort
providing bone microstructural traits revealed that a genetic
variant in the RANKL locus is associated with not only cortical
vBMD but also with cortical porosity. The FMN2/GREM2 locus,
on the other hand, is robustly associated with not only trabecular
vBMD but also trabecular number and thickness as well as
GREM2 expression in human osteoblasts and fracture risk.
Using the same pQCT cohorts as evaluated in the present
study, we have recently identified a missense variant in the
WNT16 gene to be associated with cortical bone thickness [18].
Subsequent functional studies revealed that Wnt16 inactivated
mice had reduced cortical bone thickness, providing strong
evidence that WNT16 is an important regulator of cortical bone
thickness. In the present discovery GWAS-meta-analysis, we
identified genome-wide significant cortical vBMD signals in four
loci and a trabecular vBMD signal in one locus and all these
signals were significantly replicated in the MrOS Sweden cohort.
One of the identified cortical vBMD loci (LOC285735) and the
identified trabecular vBMD locus (FMN2) are novel bone-related
loci while the remaining three identified cortical vBMD loci have
been previously reported to be associated with aBMD. [2,6,19].
Although the number of subjects included in the present discovery
GWAS meta-analyses of vBMD (cortical vBMD n=5878;
trabecular vBMD n=2500) was substantially lower than the
number of subjects included in a recent large-scale aBMD GWA
meta-analysis (discovery cohort n = 32,961; [2]), the identification
of novel bone-related loci in the trabecular and cortical vBMD
analyses is not surprising as the correlations between aBMD on the
one side and cortical and trabecular vBMDs on the other side are
low/modest. In addition, the genetic variants associated with
cortical and trabecular bone parameters, respectively, differed,
and were also distinct from the WNT16 locus recently identified to
be associated with cortical bone thickness [18], underscoring the
complexity of the genetics of bone parameters.
Conditional analysis revealed a secondary signal in the RANKL
locus and both these cortical vBMD signals were independent of
the previously reported aBMD signal (rs9533090; [2]) in this
region, demonstrating that separate signals within the same region
can have an impact on different bone traits ( = allelic heteroge-
neity). RANKL exerts its biological effects on bone by stimulating
osteoclast differentiation following interactions with its receptor,
RANK; how distinct genetic pathways might influence this
functionality in different ways, so as to influence distinct
phenotypic traits, is currently unclear. Alternatively, one of these
signals may be in LD with a marker at a different gene responsible
for mediating the genetic effect in question, or else represent a
variant which although trans to a structural gene, affects
transcription at other sites [20]. The cortical vBMD SNPs
rs7839059 (TNFRSF11B locus) was also nominally (p,0.05)
significantly associated with trabecular vBMD, although with less
pronounced effect size, suggesting that this SNP does not
exclusively have an impact on cortical bone. The present report
describing two independent RANKL signals and one OPG signal
with an impact on cortical vBMD provides further evidence that
the RANK/RANKL/OPG axis affects the skeleton at least in part
by influencing volumetric apparent density of cortical bone. It is
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tempting to speculate that changes in cortical vBMD contribute to
the recent observations that the RANKL inhibitor denosumab
reduces fracture risk [10,21,22]. Consistent with this possibility,
administration of denosumab has been found to increase femoral
cortical vBMD in mice with a knock-in of humanized RANKL
[23].
The second strongest genetic signal for cortical vBMD was
located on chromosome 6 (rs271170), 93.4 kb upstream of
LOC285735. This is a novel bone-related signal and further
targeted sequencing efforts and functional studies are required to
characterize this signal. Several clinical and preclinical studies
have clearly demonstrated that ESR1 is an important regulator of
both female and male bone health [24–28] but the present study is
first to provide genetic evidence that this receptor influences the
volumetric apparent density of cortical bone. This finding is of
importance as Khosla and co-workers recently proposed that the
main physiological target for estrogen in bone is cortical and not
trabecular bone [24].
A significant signal (rs9287237) for trabecular vBMD was
identified on chromosome 1 located in the intron region of the
FMN2 gene. The combined effect size of this signal was substantial
with an increase of 0.19 SD per T allele. FMN2 is a gene that is
expressed in oocytes and is required for progression through
metaphase of meiosis 1 but it is not previously reported to
influence the skeleton [29]. However, a genetic variant within
FMN2 has been associated with coronary heart disease [30]. The
rs9287237 SNP is located slightly (55.7 kb) downstream of
GREM2 (= PRDC), which is an extracellular antagonist of bone
morphogenetic proteins (BMPs) and it inhibits osteoblastic
differentiation [31,32], making it an alternative plausible candi-
date gene underlying the rs9287237 association with trabecular
vBMD. Importantly, eQTL analyses in human osteoblasts
demonstrated that the trabecular vBMD-associated SNP
(rs9287237) was significantly associated with expression of the
nearby GREM2 gene, indicating that GREM2 is a strong
candidate for mediating the trabecular vBMD association at
rs9287237. However, further targeted sequencing efforts and
functional studies are required to characterize this signal.
There are known sex differences in bone traits in mice [33–36].
Similarly, some genome-wide linkage analyses in humans have
reported sex-specific results. In a whole–genome linkage analysis
stratified by sex, sex-specific QTLs were found in the Framingham
sample [37]. Furthermore, in a meta-analysis that included data
from nine whole-genome linkage scans for aBMD, several sex-
specific QTLs were observed [38]. To our knowledge there is only
one reported genome-wide significant aBMD signal, located on
the X-chromosome (Xp22.31), which displays significant sex
heterogeneity [2]. This signal was only significant in men and the
same signal was also shown to be associated with male serum
testosterone levels [39]. Sex-specific analyses in the present study
revealed that all identified cortical vBMD signals were significantly
associated with cortical vBMD in both men and women with
effects in the same direction. Nevertheless, the magnitude of the
effect sizes differed significantly according to sex for three of the
identified hits. Importantly, the effect sizes of the RANKL and
ESR1 signals were more than three (0.21 SD vs. 0.06 SD) and two
(0.12 vs. 0.05 SD) times larger, respectively, in men than in
women. The smaller effect within females observed for rs1021188
in the RANKL region is mainly driven by ALSPAC, and there may
be other reasons (such as younger age) why this study showed a
smaller effect. However, the consistent results between ALSPAC
and the YFS provide some evidence against the differences being
driven primarily by age. The relative strong ESR1 signal in men
supports experimental and clinical studies, demonstrating that
estrogens are crucial for male bone health [24,25,27,40].
We examined genetic effects across cohorts encompassing a
relatively broad age range, including 15 year old participants from
ALSPAC who were still attaining peak bone mass, to older men
from MrOS Sweden starting to show age-related bone loss.
Inclusion of an older cohort had the advantage of providing an
opportunity to study relationships with fracture risk. However, this
design may have reduced the power to detect genetic associations
by introducing greater heterogeneity. In contrast to aBMD,
vBMD has been reported to change relatively little from
adolescence to mid-life suggesting that analyses combining cohorts
of different ages might be more informative when based on this
trait [41]. However, recent follow up studies based on the GOOD
cohort revealed substantial changes in cortical vBMD in the late
teens and early twenties, at least in males [42]. Hence the
suggestion that certain genetic associations with cortical vBMD
were weaker in ALSPAC compared with other cohorts may reflect
attenuation of effect during the consolidation of cortical bone
whilst attaining peak bone mass.
Age-related changes in bone include microstructural deteriora-
tion, such as trabecular perforation, thinning, and loss of
connectivity, as well as increased cortical porosity [8,9]. These
bone microstructural parameters are believed to have an aBMD-
independent influence on fracture risk and they can be analyzed
by HRpQCT. The present study is the first to identify genetic loci
associated with cortical and trabecular bone microstructural
parameters as analyzed by HRpQCT. The SNP in the RANKL
region with the strongest association with cortical vBMD was also
significantly associated with cortical porosity but, as expected, in
the reverse direction. This finding suggests that a genetic variant in
the RANKL locus influences cortical vBMD, at least partly, via
effects on cortical porosity. Importantly, this signal in the RANKL
region was independent from the previously reported aBMD
signal in the same region [2]. Analyses of trabecular bone
microstructure demonstrated that the trabecular vBMD SNP
rs9287237 in the FMN2/GREM2 locus was significantly associated
with several trabecular but not cortical bone microstructure
parameters. When evaluated in the five-year follow-up visit in the
GOOD cohort, each T allele of this SNP resulted in a substantial
increase in trabecular vBMD (0.32 SD), trabecular bone fraction
(BV/TV 0.29 SD), trabecular number (0.15 SD), and trabecular
thickness (0.18 SD). Thus, a genetic variant in the FMN2/GREM2
locus influences trabecular vBMD via substantial effects on both
trabecular number and thickness. Although, the present study is
the first to report on genetic variants associated with microstruc-
tural bone-parameters, the analyses were candidate-based as a
follow-up of our initial cortical and trabecular vBMD GWA meta-
analyses. In order to identify novel genetic loci for bone
microstructural parameters in a hypothesis-free manner, well-
powered HRpQCT cohorts with genome-wide genotype data
available need to be established.
We believe that our study provides strong evidence that
previous large-scale GWA meta-analyses of the complex bone
trait aBMD did not have the capability to identify a number of
important loci with an impact on aspects of micro-architecture
which may have important effects on fracture risk but be poorly
reflected by overall aBMD measurements. We, therefore, propose
that future well-powered pQCT and HRpQCT GWA meta-
analyses of these specific bone structural traits will add useful
information and might result in the identification of novel
osteoporosis drug targets and provide novel aBMD-independent
genetic markers for the prediction of fracture risk.
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The implication of our results suggesting that cortical and
trabecular bone compartments are under distinct genetic control is
consistent with the fact that patients with idiopathic osteoporosis
may present with a predominantly trabecular or cortical bone
phenotype [43]. Although the lumbar spine and hip both comprise
a mixture of bone types, the former has a relatively high
proportion of trabecular bone, whereas the hip has a higher
proportion of cortical bone. Hence, patients presenting with a
disproportionate decrease in lumbar spine aBMD, which are well
recognized, presumably have greater reductions in trabecular
compared to cortical BMD [44]. Further studies are required to
determine whether genetic variation in the FMN2/GREM2 locus
helps to explain this type of presentation.
The genetic variant in the FMN2/GREM2 locus was associated
with fracture risk and prevalent X-ray verified vertebral fractures
in the MrOS Sweden cohort. However, further large-scale studies
are required to replicate the fracture findings of this SNP.
Collectively our data demonstrate that each extra T allele of
rs9287237 is associated with decreased expression of the BMP
antagonist GREM2 in osteoblasts, increased trabecular vBMD
and decreased fracture risk. As previous in vitro studies have
demonstrated that GREM2 inhibits osteoblast differentiation, we
propose that rs9287237 is involved in the regulation of GREM2
expression in osteoblasts, which in turn regulates osteoblast
differentiation and thereby the amount of trabecular bone and
fracture risk [31,32].
In conclusion, we identified five genetic loci associated with
trabecular or cortical vBMD. Two of these (FMN2/GREM2 and
LOC285735) are novel bone-related loci while the other three have
previously been reported to be associated with aBMD. The genetic
variants reported to be associated with cortical and trabecular
bone parameters differed and were also distinct from the WNT16
locus recently identified to be associated with cortical thickness
[18], underscoring the complexity of the genetics of bone
parameters. Finally, we propose that a genetic variant in the
RANKL locus influences cortical vBMD, at least partly, via effects
on cortical porosity, and that a genetic variant in the FMN2/
GREM2 locus influences trabecular vBMD and fracture risk via
substantial effects on both trabecular thickness and number.
Materials and Methods
Ethics statement
All study participants provided informed written consent.
Approval by local institutional review boards was obtained in all
studies.
GOOD cohort
Participants. The Gothenburg Osteoporosis and Obesity
Determinants (GOOD) study was initiated to determine both
environmental and genetic factors involved in the regulation of
bone and fat mass [45,46]. Young, Caucasian men were randomly
identified in the greater Gothenburg area in Sweden using
national population registers, contacted by telephone, and invited
to participate. Enrolled subjects were between 18 and 20 years of
age. There were no other exclusion criteria, and 49% of the study
candidates agreed to participate (n = 1,068). Five years later, the
study subjects in the original GOOD study were contacted by
letter and telephone and invited to participate in the 5-yr follow-up
study. Of the original 1,068 subjects, 833 men, 24.160.6 yr of age,
were included in the follow-up study (78% of the original
population) [42]. The GOOD study was approved by the local
ethics committee at University of Gothenburg. Oral and written
informed consent was obtained from all study participants. Weight
was measured to the nearest 0.1 kg and height was measured using
a wall-mounted stadiometer.
pQCT measurements. Cortical volumetric BMD (not
including the bone marrow) was measured on a single tibial
diaphyseal slice (at 25% of the bone length in the proximal
direction of the distal end) using the Stratec XCT2000 (Germany)
at both the baseline visit and the five-year follow-up visit in the
GOOD cohort [42,46]. A threshold routine was used for defining
cortical bone, which specified a voxel with a density .710 mg/
cm3 as cortical bone. Trabecular vBMD (mg/cm3) was measured
using a scan through the metaphysis (at 4% of the bone length in
the proximal direction of the distal end) of the tibia. Tibia length
was measured from the medial malleolus to the medial condyle.
The CVs were ,1% for all pQCT measurements. Both pQCT
measurements and genotype information were available for 938
study subjects.
HRpQCT measurements. A high-resolution 3D pQCT
device (XtremeCT; Scanco Medical AG, Bru¨ttisellen, Switzerland)
was used to scan the ultradistal tibia of the nondominant leg at the
five-year follow-up visit in the GOOD cohort [47]. Anatomically
formed carbon fiber shells, especially designed for each type of
limb (Scanco Medical), were used to immobilize the subject’s leg
during the scan. The measurements of the volume of interest in the
ultradistal tibia, 1 cm in the proximal direction and the whole
cross-section in transversal direction, were carried out according to
a standardized protocol previously described [47]. Briefly, a
reference line was manually placed at the center of the end plate of
the distal tibia. The first tomographic slice started 22.5 mm
proximal to the reference line. A total of 110 parallel slices, with a
nominal isotropic resolution (voxel size) of 82 mm, were obtained,
delivering a 3D representation of an approximately 9-mm section
of the tibia in the proximal direction. The entire volume of interest
was automatically separated into cortical and trabecular region.
From this separation and by previously described methods to
process the data, we obtained trabecular bone volume fraction
(BV/TV, percent), trabecular number (TbN; millimeters21),
trabecular thickness (TbTh; micrometers) and trabecular separa-
tion (TbSp; micrometers). For the cortical porosity, we used the
manufacturer’s software, which uses an approach published
recently by several groups [48,49] and described in detail by
Burghardt and colleagues [8,50]. The coefficients of variation
(CVs) for the used bone measurements were obtained by three
repeated measurements according to the standardized protocol on
two subjects. The CVs ranged from 0.04 to 1.6%. Both HRpQCT
measurements and genotype information were available for 729
study subjects.
Discovery set genotyping. Genotyping was performed with
Illumina HumanHap610 arrays at the Genetic Laboratory,
Department of Internal Medicine, Erasmus Medical Center,
Rotterdam, the Netherlands. Genotypes were called using the
BeadStudio calling algorithm. Genotypes from 938 individuals
passed the sample quality control criteria (exclusion criteria:
sample call rate ,97.5%, excess autosomal heterozygosity .0.33
(FDR ,0.1%), duplicates and/or first degree relatives identified
using IBS probabilities (.97%), ethnic outliers (3 SD away from
the population mean) using multi-dimensional scaling analysis with
four principal coordinates). Across 22 duplicate samples, genotype
concordance exceeded 99.9%. We carried out imputation to
HapMap (NCBI build 36, release 21 and 22 for X chromosome
and autosomes, respectively) (after excluding SNPs with MAF
,1%, SNP call rate ,98% and HWE p value,161026) using
Mach 1.0, Markov Chain Haplotyping, giving a total of 2,608,508
SNPs.
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YFS cohort
Participants. The Cardiovascular Risk in Young Finns
Study (YFS) is an ongoing multi-centre follow-up of atherosclerosis
risk factors in young Finns of Caucasian origin [51]. The first
cross-sectional survey conducted in 1980 comprised a total of
3,596 subjects (83% of those invited) aged 3, 6, 9, 12, 15 and 18
years. The subjects were randomly selected from the national
population register from five university cities in Finland (Helsinki,
Turku, Tampere, Kuopio and Oulu) and the rural municipalities
in their vicinity. In 2008, 1,884 subjects (1,058 women and 826
men) aged 31–46 years participated in pQCT measurements
organized in five study centers (Turku, Helsinki, Tampere, Oulu
and Kuopio) between February and December 2008. Trained
technologists in each center performed the measurements. The
same pQCT device was used in all study centers (Stratec XCT
2000R). Pregnant women were excluded from the pQCT
measurements. Subjects gave written informed consent. The study
protocol was approved by the local ethics committees of the
participating universities and complied with national legislation.
pQCT measurements. Cortical volumetric BMD was mea-
sured on a single tibia diaphyseal slice (at 30% of the bone length
in the proximal direction of the distal endplate ot the tibia) using
the Stratec XCT2000 (Germany). A threshold routine was used
for defining cortical bone, which specified a voxel with a density
.710 mg/cm3 as cortical bone. Trabecular vBMD (mg/cm3) was
measured using a scan through the metaphysis (at 5% of the bone
length in the proximal direction of the distal endplate) of the tibia.
Tibia length was measured from the medial malleolus to the
medial condyle. The CVs were ,2.6% for all pQCT measure-
ments. Both pQCT measurements and genotype information were
available for 1558 study subjects.
Discovery set genotyping. Genomic DNA was extracted
from peripheral blood leukocytes using a commercially available
kit and Qiagen BioRobot M48 Workstation according to the
manufacturer’s instructions (Qiagen, Hilden, Germany). Geno-
typing was done for 2556 samples using custom build Illumina
Human 670 k BeadChip at the Welcome Trust Sanger Institute.
Genotypes were called using the Illuminus clustering algorithm. 56
samples failed Sanger genotyping pipeline QC criteria (i.e.,
duplicated samples, heterozygosity, low call rate, or Sequenom
fingerprint discrepancy). From the remaining 2500 samples one
sample failed gender check, three were removed due to low
genotyping call rate (,0.95) and 54 samples for possible
relatedness (pi-hat.0.2). 11,766 SNPs were excluded based on
HWE test (p,=161026), 7,746 SNPs failed a missingness test
(call rate ,0.95) and 34,596 SNPs failed frequency test
(MAF,0.01). After quality control there were 2,442 samples and
546,677 genotyped SNPs available for further analysis. Genotype
imputation was performed using MACH 1.0 and HapMap II
CEU (NCBI build 36, release 21 and 22 for X chromosome and
autosomes, respectively) samples as the reference set.
ALSPAC cohort
Participants. The Avon Longitudinal Study of Parents and
their Children (ALSPAC) is a geographically based birth cohort
study investigating factors influencing the health, growth, and
development of mainly Caucasian children [52]. All pregnant
women resident within a defined part of the former county of
Avon in South West England with an expected date of delivery
between April 1991 and December 1992 were eligible for
recruitment, of whom 14,541 were enrolled (http://www.alspac.
bris.ac.uk). Both mothers and children have been extensively
followed from the 8th gestational week onwards using a
combination of self-reported questionnaires, medical records and
physical examinations. Ethical approval was obtained from the
ALSPAC Law and Ethics committee and relevant local ethics
committees, written informed consent was provided by all parents.
Blood samples were taken and DNA extracted as previously
described [53]. Height was measured using a Harpenden
stadiometer (Holtain Limited, Wales) and weight using a Tanita
Body Fat Analyser.
pQCT measurements. pQCT scans were performed on
approximately 4,500 children when they attended the age 15
research clinic. Cortical vBMD was measured on a single slice at
the mid tibia (50%) using the Stratec XCT2000L (Germany). A
threshold routine was used for defining cortical bone, which
specified a voxel with a density.650 mg/cm3 as cortical bone. Of
the 4500 pQCT scans obtained in ALSPAC 89 were rejected as
being of insufficient quality. The CVs for cortical volumetric BMD
based on 139 ALSPAC subjects scanned a mean of 31 days apart,
was 1.3%.
Discovery set genotyping. 9,912 ALSPAC individuals were
genotyped using the Illumina HumanHap550 quad genome-wide
SNP genotyping platform by 23andMe, subcontracting the
Wellcome Trust Sanger Institute, Cambridge, UK and the
Laboratory Corporation of America, Burlington, NC, US.
Markers with ,1% minor allele frequency .5% missing
genotypes or which failed an exact test of Hardy-Weinberg
equilibrium (HWE) (p,561027) were excluded from further
analysis. We also excluded any individuals who did not cluster with
the CEU individuals in multidimensional scaling analysis, who had
.3% missing data, minimal or excessive heterozygosity (.34.5%
or ,32% for the Sanger data and .33% or ,31% for the
LabCorp data), evidence of cryptic relatedness (.10% IBD) and
any individuals with incorrect gender assignments. After data
cleaning we were left with 8365 unrelated individuals with
genome-wide genotyping, and 500,541 SNPs. We carried out
imputation using MACH 1.0.16, Markov Chain Haplotyping,
using CEPH individuals from phase 2 of the HapMap project as a
reference set (NCBI build 36, release 21 and 22 for X chromosome
and autosomes, respectively). Of the 8,365 individuals with
imputed genotype data, 3,382 also had pQCT data.
MrOS Sweden cohort (replication)
Participants. The Osteoporotic Fractures in Men (MrOS)
study is a prospective multicenter study including older Caucasian
men in Sweden (n= 3,014), Hong Kong (.2,000), and the United
States (.6,000). In the present study, associations between
candidate polymorphisms and skeletal parameters were investi-
gated in the Swedish cohort, which consists of three sub-cohorts
from three different Swedish cities (n = 1,005 in Malmo¨, n= 1,010
in Gothenburg, and n= 999 in Uppsala) [54]. Study subjects were
randomly identified using national population registers, contacted
and asked to participate. To be eligible for the study, the subjects
had to be able to walk without assistance, provide self-reported
data, and sign an informed consent; there were no other exclusion
criteria. The study was approved by the ethics committees at the
Universities of Gothenburg, Lund, and Uppsala. Informed consent
was obtained from all study participants.
pQCT measurements. Cortical volumetric BMD (not
including the bone marrow) was measured on a single tibial
diaphyseal slice (at 38% of the bone length in the proximal
direction of the distal end) using the Stratec XCT2000 (Germany)
[10]. A threshold routine was used for defining cortical bone,
which specified a voxel with a density .710 mg/cm3 as cortical
bone. Trabecular vBMD (mg/cm3) was measured using a scan
through the metaphysis (at 4% of the bone length in the proximal
direction of the distal end) of the tibia. Tibia length was measured
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from the medial malleolus to the medial condyle. The CVs were
,1% for all pQCT measurements. Adjustments for study centre
were performed.
Replication set genotyping. Genotyping of SNPs identified
in the GWAS meta-analysis was carried out at KBioscience using a
competitive allele specific PCR (KASP) genotyping chemistry. The
genotyping call rate was .97%.
eQTL analysis in human osteoblasts
SNPs associated with vBMD at the genome-wide significance level
as reported here were tested for association with resting or induced
gene expression of neighbouring gene transcripts, in primary human
osteoblasts derived from 113 (51 female and 62 male donors,
respectively) unrelated Swedish donors. Detailed cell culture and
analysis methods have been described in detail [15,16]. Briefly,
expression profiling of untreated, dexamethasone, BMP-2 and
PGE2-treated cells each with up to three biological replicates was
performed using the Illumina HumRef-8 BeadChips according to the
protocol supplied by the manufacturer. Genotyping for genotype-
expression association was performed using Illumina HapMap 550 k
Duo chip. Individuals with low genotyping rate and SNPs showing
significant deviation from Hardy-Weinberg equilibrium (P,0.05)
were excluded. Similarly low frequency (MAF,0.05) SNPs and SNPs
with high rates of missing data were excluded. Genotypes from
samples that passed quality control (N=103) were imputed for all
SNPs (n=478,805) oriented to the positive strand from phased
(autosomal) chromosomes of the HapMap CEU Phase II panel
(release 22, build 36) using MACH 1.0) [55]. A cut-off of R2,0.3
were used to remove poorly imputed markers. Association of imputed
genotypes using estimated genotype probabilities with nearby
expression traits (defined as 6250 kb window flanking the gene)
were performed using a linear regression model implemented in the
MACH2QTL software with sex and age as covariates.
Assessment of incident fractures in MrOS Sweden
Participants were followed for 5.4 years on average after the
baseline examination. The follow-up time was recorded from the
date of the baseline visit to the date of the first fracture, the date of
death, or end of the present follow-up interval. When a subject
sustained a first fracture at different sites during the follow-up, the
various fractures and the follow-up time for each respective first
fracture type were included in the analyses. Complete follow-up
was possible because central registers covering all Swedish citizens
were used to identify the subjects and the time of death for all
subjects who died during the study, and these analyses were
performed after the time of fracture validation. At the time of
fracture evaluation, the computerized X-ray archives in Malmo¨,
Go¨teborg, and Uppsala were searched for new fractures occurring
after the baseline visit, using the unique personal registration
number, which all Swedish citizens have. All fractures reported by
the study subject after the baseline visit were confirmed by
physician review of radiology reports. Fractures reported by the
study subject, but not possible to confirm by X-ray analyses report,
were not included in this study. All validated fractures and hip
fractures were evaluated. Information about the type of trauma
associated with the incident fractures was not available. Fracture
rates were expressed as the number of subjects with first fractures
per 1000 person-years (Table S6).
Assessment of prevalent vertebral fractures in MrOS
Sweden
In Gothenburg and Malmo¨, 1445 men had an X-ray of the
lateral thoracic and lumbar spine at baseline. All vertebral
fractures were evaluated by an expert radiologist. If the vertebral
body had a reduced height of 3 mm or more compared with the
vertebra above, it was classified as a vertebral fracture [56].
Statistical methods
The ALSPAC (n= 3382), YFS (n = 1558) and GOOD
(n= 938) discovery cohorts contributed to the cortical vBMD
genome-wide meta-analysis while the YFS and GOOD discovery
cohorts contributed to the trabecular vBMD genome-wide meta-
analysis. We analyzed only those imputed SNPs which had a
minor allele frequency of .0.01 and an r2 imputation quality
score of .0.3 in all 3 sets (n = 2,401,124). We carried out
genome-wide association analyses for cortical and trabecular
vBMDs using additive linear regression in Mach2QTL for
ALSPAC, ProbABEL [57] for YFS and Mach2QTL on GRIMP
[19] for the GOOD analyses. We included age, sex, height and
weight(ln) as covariates. We carried out meta-analyses of the
results from the three cohorts using the inverse variance method
in METAL. Standardized betas and standard errors from each
study were combined using a fixed effect model which weights
the studies using the inverse variance and applying genomic
control to individual studies and the combined results. Genome-
wide significance was taken to be p,561028. We also repeated
the analyses in each of the three discovery cohorts, conditional
on these top SNPs, to identify any additional independent
associations in the regions. We selected one SNP for replication
in the MrOS Sweden cohort from each independent region that
had a p,561028 as well as a secondary SNP from the RANKL
region which appeared to influence cortical vBMD. Additive
linear regression analyses were carried out for the associations
between these SNPs and cortical and trabecular vBMDs in SPSS
Statistics 17.0 for MrOS Sweden, using age, sex, height and
weight(ln) as covariates. The results of all four cohorts were
combined using a fixed effects inverse-variance meta-analysis in
Stata (version 11.2). The SNPs showing evidence for heteroge-
neity (as assessed by a chi-squared test) were also meta-analysed
using the DerSimonian & Laird random effects method.
Correlations between bone traits in the GOOD cohort were
tested and presented as Spearman’s rank correlation coefficients
(rho). The difference of the allelic association effects between
males and females was tested using a two sample z-test.
Cox proportional hazards models were used to study the
associations between SNPs and incident fractures. Prevalent
vertebral fractures were analyzed using binary logistic regression
models.
Estimation of the genetic correlation between cortical
and trabecular vBMD
In order to estimate the genetic correlation between cortical and
trabecular vBMD we ran a bivariate REML analysis using the
GCTA software package in the GOOD cohort, having both
cortical and trabecular vBMDs measurements available [14]. This
method essentially decomposes the covariance between the two
traits into a part explained by common genetic variation that is
tagged by markers on the SNP chip and a residual part that is not.
It is then possible to use these estimates to estimate a genetic
correlation between the two.
Supporting Information
Table S1 Discovery meta-analysis of cortical and trabecular
vBMDs.
(PDF)
Genetic Determinants of Bone Microstructure
PLOS Genetics | www.plosgenetics.org 13 February 2013 | Volume 9 | Issue 2 | e1003247
Table S2 Cortical vBMD SNPs conditioned on known aBMD
SNPs.
(PDF)
Table S3 Association of top cortical and trabecular vBMD
signals with pQCT and HRpQCT parameters in the GOOD
cohort at the five-year follow-up visit.
(PDF)
Table S4 Associations with cortical and trabecular vBMD for 64
reported genome-wide significant aBMD SNPs.
(PDF)
Table S5 eQTL analysis in human osteoblasts.
(PDF)
Table S6 Characteristics of the MrOS Sweden fracture cohort.
(PDF)
Table S7 Associations between cortical and trabecular vBMD
SNPs and fractures in MrOS Sweden.
(PDF)
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